



# KMS NICHE PRODUCT LIST

## 2026

**“PUTTING HEALTH FIRST IS OUR MOTTO”**



+91 97898 75194  
+91 8008422119



[www.kmshc.com](http://www.kmshc.com)



Door. No 6, Kamarajar St, East  
Tambaram, Selaiyur, Chennai,  
Tamil Nadu 600059

Product Name	Current Approved Dosage form and Strength	Approved for Therapeutic indications	KMS Formulation	Status
Amlodipine	Oral Solution Eq. 1mg/ mL	Antihypertensive [Adults and children 6 years of age and older]	Oral Solution [Non Infringement approach]	6 Months stability Completed
Nimodipine	Oral solution 3mg/ mL, 6 mg/ mL	CNS - Subarachnoid hemorrhage	Oral Solution [Competitive Generic Therapy Approach]	Under Development
Rosuvastatin	Tablets 10mg, 20mg, 40mg	Hyperlipidemia	Oral Suspension/ Oral Solution	6 Months stability Completed
Sevelamer Carbonate	Powder for Oral Suspension 800mg/ Packet, 2.4 gm/ Packet	Hyperphosphatemia	Oral Solution	Under Development
Solifenacin Succinate	Tablets & Oral Suspension 5mg, 10mg, 1mg/ mL	Neurogenic detrusor overactivity (in pediatric patients)	Both Suspension and Oral Solution	6Months stability Completed
Deferasirox	Tablet For Oral Solution 125mg / 250mg and 500mg	Transfusional hemosiderosis in patients 2 years of age and older	Oral Suspension	6Months stability Completed
Trazodone hydrochloride	Tablets 50mg, 100mg, 150mg, 300mg	Depression and Anxiety	Oral Solution	Under Development
Eltrombopag olamine	For suspension Eq base 12.5 mg/sachet, Eq base 25 mg/sachet	Thrombocytopenia	RTU Suspension	12Months stability Completed
Omega 3 fatty acid	Suspension 1000mg (EPA +DHA+ Quercitin)	Hypertriglyceridemia / Heart disease risk reduction	Oral Solution	Read for Commercials
<b>READY TO USE Injectable Solution (with differentiated Approach/ Non-Infringing)</b>				
Tacrolimus	Injectable Solution 5MG/ML	Graft rejection prevention in HSCT (hematopoietic stem cell transplantation)	Injectable Solution [Design around composition to address any stability challenges	Ready for technology Transfer





Product Name	Current Approved Dosage form and Strength	Approved for Therapeutic indications	KMS Formulation	Status
Thiotepa	Powder for iv Injection 5mg/ml	Graft rejection prevention in HSCT (hematopoietic stem cell transplantation)	RTU	Ready for technology Transfer
Triptorelin Pamoate	Powder for Intramuscular Injection Eq. 22.5mg base/ Vial	Advanced prostate cancer (palliative treatment)	RTU depot injection	Under Development
<b>SOLID ORALS (with differentiated Approach/ Non-Infringing)</b>				
Elagolix Sodium	Tablet ER EQ 200MG BASE, EQ 150MG BASE	Endometriosis pain (Moderate to severe)	Extended Release Tablet [Non Infringment approach]	Under Development
Sucro Ferric Oxyhydroxide	Tablet 500mg	Hyperphosphatemia in chronic kidney disease	Tablet with differentiation approach	Ready for technology Transfer
Rimegepant Sulfate	Tablet Orally Disintegrating EQ 75MG Base	Migraine (acute treatment)	Tablet with differentiation approach	Under Development
<b>TOPICALS (with differentiated Approach/ Non-Infringing)</b>				
Gabapentin	Capsule, Tablet, Oral Solution Capsule (100mg, 200mg), Tablet (300mg, 400mg, 600, 800mg), Oral Solution (250mg/ 5 mL)	Neuropathic Pain	Cream	POC established/ Under development
Doxepin	Oral Concentrate Oral Concentrate - Eq. to 10mg Base / ml	Major depressive disorder	Oral Liquid [Differentiation with dose reduction]	POC established/ Under development
Dapsone	Topical Gel Topical Gel - 5% AND 7.5%	Acne Vulgaris	Topical Gel [Differentiated approach]	POC established/ Under development
Clindamycin and Benzoyl Peroxide	Topical Gel Benzoyl Peroxide - 2.5% / 3.75% / 5% Clindamycin Phosphate - 1.2% / 1.0%	Acne Vulgaris	Topical Gel [Differentiated approach]	POC established/ Under development

